Respiratory medicine
Is an antibody against IL-9 safe to give people with asthma?
Open access · cc by · source: Europe PMC
Repeated injections of an experimental anti-IL-9 antibody were tolerated about as well as placebo in people with mild asthma, with early hints that it might blunt exercise-triggered airway narrowing.
Study at a glance
- Design
- RCT — Two randomized, double-blind, placebo-controlled phase 2a trials: study 1 escalated weight-based doses (3:1 drug:placebo); study 2 tested a fixed 50 mg dose (2:1) with exercise challenge and was halted early.
- N
- No single N: 36 adults randomized in study 1 (all included in safety analyses) and 11 in study 2 (9 evaluable for the exercise-challenge outcome).
- Population
- Adults with mild persistent asthma (study 1) or stable mild-to-moderate asthma with exercise-induced bronchoconstriction (study 2), recruited at US multicentre sites
- Outcome
- Primary: safety and tolerability (adverse events) of repeated subcutaneous MEDI-528; secondary/exploratory: pharmacokinetics, anti-drug antibodies, exercise-induced fall in FEV1, exacerbations, symptoms and quality of life
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
Adverse events, including severe ones, occurred at similar rates on drug and placebo, and no participant developed antibodies against MEDI-528. Blood levels rose roughly in proportion to dose and the drug's half-life was about 35-38 days. Resting lung function, rescue-inhaler use and quality of life did not differ, and the lower exacerbation count on drug (1 of 27 vs 2 of 9) was not statistically significant. In study 2, the average maximum post-exercise drop in FEV1 at day 56 was -0.04 L on drug versus -0.60 L on placebo, and in a post hoc analysis 7 of 7 drug-treated participants met the responder definition at day 56.
Methodology
Researchers ran two placebo-controlled, double-blind trials of MEDI-528, a humanized antibody that blocks the immune signal interleukin-9. In study 1, 36 adults with mild asthma were randomized 3:1 to the drug or placebo at doses of 0.3, 1 or 3 mg/kg, injected under the skin twice weekly for 4 weeks, then followed to day 150. In study 2, 11 adults with exercise-induced bronchoconstriction received 50 mg or placebo (2:1) and did treadmill exercise challenges before and after dosing; this trial was planned with three dose cohorts but stopped after the first.
Limitations
With only 36 and 11 participants and no formal hypothesis testing for most outcomes, these trials were built to look for safety problems, not to prove the drug works; the exercise-challenge benefit comes from a handful of people at one time point, and the responder analysis was done after the fact. Study 2 was stopped early after a brain MRI abnormality that later proved to be an artifact, so its planned higher doses were never tested. Participants had mild disease, so the results say little about the severe, poorly controlled asthma the drug would ultimately target, and the studies were sponsored and largely analysed by the manufacturer.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Early-phase trials establish safety; efficacy signals from them are preliminary.
Small phase 2a RCTs of the anti-IL-9 antibody MEDI-528 in mild asthma found adverse events similar to placebo, with only a hint of reduced exercise-induced bronchoconstriction in a handful of participants.
Evidence for the claim as stated.
Early-phase trials establish safety; efficacy signals from them are preliminary.
Small phase 2a RCTs of the anti-IL-9 antibody MEDI-528 in mild asthma found adverse events similar to placebo, with only a hint of reduced exercise-induced bronchoconstriction in a handful of participants.
Scope note — 36 and 11 participants; exercise result from one time point with a post hoc responder analysis.
Limits the claim's scope: a different population, assay, or outcome.
Biologic trials in this set were run in different asthma populations: MEDI-528 in mild asthma showed early hints of benefit on exercise challenge, while quilizumab in severe uncontrolled allergic asthma failed, and its own earlier promising allergen-challenge studies had been in mild asthma. Different drugs, targets and severities mean this is a limit on generalising from mild to severe disease rather than a direct conflict.
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
Biologic trials in this set were run in different asthma populations: MEDI-528 in mild asthma showed early hints of benefit on exercise challenge, while quilizumab in severe uncontrolled allergic asthma failed, and its own earlier promising allergen-challenge studies had been in mild asthma. Different drugs, targets and severities mean this is a limit on generalising from mild to severe disease rather than a direct conflict.
Related papers in this topic
Same topic cluster — not a recommendation engine.